Literature DB >> 2507620

Bilateral central retinal vein occlusion in Waldenström's macroglobulinemia.

J H Avashia1, D F Fath.   

Abstract

Waldenström's macroglobulinemia is a rare progressive neoplastic plasma cell disorder. Hyperviscosity is a major component in primary macroglobulinemia due to the excessive production of IgM paraprotein, a tumor by-product. The ocular manifestations of hyperviscosity can include congestion of the conjunctival vessels, dilation, segmentation and tortuosity of retinal vessels, retinal hemorrhages and serous retinal detachment. This case of bilateral central retinal vein occlusion represents an uncommon complication of Waldenström's macroglobulinemia.

Entities:  

Mesh:

Year:  1989        PMID: 2507620

Source DB:  PubMed          Journal:  J Am Optom Assoc        ISSN: 0003-0244


  6 in total

Review 1.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

Review 2.  Acute hyperviscosity: syndromes and management.

Authors:  Morie A Gertz
Journal:  Blood       Date:  2018-08-13       Impact factor: 22.113

3.  Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.

Authors:  T H Williamson; A Rumley; G D Lowe
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

4.  Intravitreal Injection of Dexamethasone Implant in Serous Macular Detachment Associated with Waldenström's Disease.

Authors:  Vito Fenicia; Marco Balestrieri; Andrea Perdicchi; Giorgia Maraone; Santi Maria Recupero
Journal:  Case Rep Ophthalmol       Date:  2013-07-26

5.  Bilateral Central Retinal Vein Occlusion, multiple dental implants and severe glomerulonephtitis - Any connection?

Authors:  Monica Malaescu; Bogdana Tabacaru; Simona Stanca; Tudor Horia Stanca
Journal:  Rom J Ophthalmol       Date:  2019 Jul-Sep

6.  Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia.

Authors:  Aurélie Brolly; Claire Janon; Flavien Precausta; Jean-Marie Baudet; Salomon Yves Cohen
Journal:  Case Rep Ophthalmol       Date:  2012-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.